CN106008308A - 尼达尼布乙磺酸盐结晶 - Google Patents

尼达尼布乙磺酸盐结晶 Download PDF

Info

Publication number
CN106008308A
CN106008308A CN201510112909.0A CN201510112909A CN106008308A CN 106008308 A CN106008308 A CN 106008308A CN 201510112909 A CN201510112909 A CN 201510112909A CN 106008308 A CN106008308 A CN 106008308A
Authority
CN
China
Prior art keywords
nintedanib
crystal
crystallization
type
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201510112909.0A
Other languages
English (en)
Chinese (zh)
Inventor
王胡博
朱雪焱
郭猛
胡明通
张家松
孙九德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority to CN201510112909.0A priority Critical patent/CN106008308A/zh
Priority to EP16764201.6A priority patent/EP3269710B1/en
Priority to JP2017548117A priority patent/JP2018509421A/ja
Priority to PCT/CN2016/076110 priority patent/WO2016146020A1/zh
Priority to US15/558,050 priority patent/US10292965B2/en
Priority to RU2017136104A priority patent/RU2708683C2/ru
Priority to CN201680014054.0A priority patent/CN107428686A/zh
Publication of CN106008308A publication Critical patent/CN106008308A/zh
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B28/00—Production of homogeneous polycrystalline material with defined structure
    • C30B28/04—Production of homogeneous polycrystalline material with defined structure from liquids
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/10—Inorganic compounds or compositions
    • C30B29/46—Sulfur-, selenium- or tellurium-containing compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
CN201510112909.0A 2015-03-13 2015-03-13 尼达尼布乙磺酸盐结晶 Withdrawn CN106008308A (zh)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN201510112909.0A CN106008308A (zh) 2015-03-13 2015-03-13 尼达尼布乙磺酸盐结晶
EP16764201.6A EP3269710B1 (en) 2015-03-13 2016-03-11 Nintedanib diethanesulfonate salt crystal and preparation method and use thereof
JP2017548117A JP2018509421A (ja) 2015-03-13 2016-03-11 ニンテダニブジエタンスルホン酸塩結晶並びにその製造方法および使用
PCT/CN2016/076110 WO2016146020A1 (zh) 2015-03-13 2016-03-11 尼达尼布二乙磺酸盐晶体及其制备方法和用途
US15/558,050 US10292965B2 (en) 2015-03-13 2016-03-11 Nintedanib diethanesulfonate salt crystal and preparation method and use thereof
RU2017136104A RU2708683C2 (ru) 2015-03-13 2016-03-11 Кристаллическая соль нинтеданиба диэтансульфоната и способ ее получения и применения
CN201680014054.0A CN107428686A (zh) 2015-03-13 2016-03-11 尼达尼布二乙磺酸盐晶体及其制备方法和用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510112909.0A CN106008308A (zh) 2015-03-13 2015-03-13 尼达尼布乙磺酸盐结晶

Publications (1)

Publication Number Publication Date
CN106008308A true CN106008308A (zh) 2016-10-12

Family

ID=56918371

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510112909.0A Withdrawn CN106008308A (zh) 2015-03-13 2015-03-13 尼达尼布乙磺酸盐结晶
CN201680014054.0A Pending CN107428686A (zh) 2015-03-13 2016-03-11 尼达尼布二乙磺酸盐晶体及其制备方法和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680014054.0A Pending CN107428686A (zh) 2015-03-13 2016-03-11 尼达尼布二乙磺酸盐晶体及其制备方法和用途

Country Status (6)

Country Link
US (1) US10292965B2 (https=)
EP (1) EP3269710B1 (https=)
JP (1) JP2018509421A (https=)
CN (2) CN106008308A (https=)
RU (1) RU2708683C2 (https=)
WO (1) WO2016146020A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113024439A (zh) * 2021-03-28 2021-06-25 郑州大学 尼达尼布乙磺酸盐新晶型ⅰ的制备

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110072849A (zh) * 2017-03-14 2019-07-30 新源生物科技股份有限公司 3-z-[1-(4-(n-((4-甲基-哌嗪-1-基)-甲羰基)-n-甲基-氨基)-苯氨基)-1-苯基-亚甲基]-6-甲氧羰基-2-吲哚满酮的晶型
CA3082714A1 (en) 2017-11-17 2019-05-23 Fermion Oy Synthesis of a 2-indolinone derivative known as intermediate for preparing nintedanib

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
EP1870400A1 (en) * 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
BRPI0820689A2 (pt) * 2007-12-03 2019-09-24 Boehringer Ingelheim Int processo de produção de um derivado de indolinona
WO2012068441A2 (en) * 2010-11-19 2012-05-24 Ratiopharm Gmbh Intedanib salts and solid state forms thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113024439A (zh) * 2021-03-28 2021-06-25 郑州大学 尼达尼布乙磺酸盐新晶型ⅰ的制备

Also Published As

Publication number Publication date
US20180064684A1 (en) 2018-03-08
EP3269710B1 (en) 2020-01-01
RU2708683C2 (ru) 2019-12-11
RU2017136104A (ru) 2019-04-15
RU2017136104A3 (https=) 2019-07-17
WO2016146020A1 (zh) 2016-09-22
JP2018509421A (ja) 2018-04-05
EP3269710A4 (en) 2018-08-22
US10292965B2 (en) 2019-05-21
EP3269710A1 (en) 2018-01-17
CN107428686A (zh) 2017-12-01

Similar Documents

Publication Publication Date Title
JP6170146B2 (ja) チロシンキナーゼ阻害剤二マレイン酸塩のｉ型結晶およびその製造法
JP6720280B2 (ja) 新規アベキシノスタット塩、関連結晶形態、それらの調製方法およびそれらを含有する医薬組成物
Khatioda et al. Solubility and in vitro drug permeation behavior of ethenzamide cocrystals regulated in physiological pH environments
JP2023025193A (ja) キナゾリン誘導体を含有する固形製剤
CN106008308A (zh) 尼达尼布乙磺酸盐结晶
Bartolomei et al. Hydrate modifications of the non-steroidal anti-inflammatory drug diclofenac sodium: solid-state characterisation of a trihydrate form
CN105777655B (zh) 萘普替尼对甲苯磺酸盐的α晶型及制备方法和含有其的药物组合物
CN104725358B (zh) 一种右旋雷贝拉唑钠水合物的晶型及其制备方法
KR20200140821A (ko) 아베마시클립의 고체-상태 형태, 그의 용도 및 제조
TWI882866B (zh) 噻吩嘧啶類化合物的晶型及其製備方法
JP2020516685A (ja) ＥＯＣ３１５ Ｍｏｄ．Ｉ結晶形化合物及びその製造方法
CN104557869B (zh) 一种吡啶胺化合物富马酸盐的晶型
CN106554315A (zh) 稳定的奥拉帕尼化合物
CN105777656B (zh) 萘普替尼对甲苯磺酸盐的β晶型及制备方法和含有其的药物组合物
CN116143647A (zh) 双氯芬酸二乙胺的新晶型及其制备方法
WO2022268063A1 (zh) 嘧啶类衍生物的晶型及其制备方法
CN103408400B (zh) 一种肌醇晶体及其制备方法和用途
CN106478598B (zh) 一种凡德他尼水合物晶体及其制备方法
CN116262697A (zh) 一种氟比洛芬和精氨酸的共晶及其制备方法
CN111320601B (zh) 一种千层纸素晶型及其制备方法
CN107344955A (zh) 一种地塞米松水合物化合物
CN106432223A (zh) 一种氘代Palbociclib结晶
CN106397401B (zh) 一种抗癌药物的晶体化合物及其制备方法
Ji et al. Exploring New Solid Forms of Antirheumatic Drug Hydroxychloroquine: Novel Salts with Sustained‐Release Performance
CN104628554A (zh) 一种非诺贝特酸晶型及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C04 Withdrawal of patent application after publication (patent law 2001)
WW01 Invention patent application withdrawn after publication

Application publication date: 20161012